Innate Pharma Sa earnings were -$56.2M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest IPHA earnings report on Dec 31, 2024 announced Q4 2024 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IPHA reported annual earnings of -$51.5M, with 512.7% growth.
What were Innate Pharma Sa's earnings last quarter?
Innate Pharma Sa (NASDAQ: IPHA) reported Q4 2024 earnings per share (EPS) of N/A, up N/A year over year. Total IPHA earnings for the quarter were N/A. In the same quarter last year, Innate Pharma Sa's earnings per share (EPS) was N/A.
As of the last Innate Pharma Sa earnings report, Innate Pharma Sa is currently losing money. Innate Pharma Sa's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$51.53 million, a 512.67% increase year over year.
What was IPHA's earnings growth in the past year?
As of Innate Pharma Sa's earnings date in Q3 2025, Innate Pharma Sa's earnings has grown year over year. IPHA earnings in the past year totalled -$56.22 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.